DUBLIN--(BUSINESS WIRE)--The "Global HIV Diagnosis & Treatment Market Research and Forecasts 2017-2022" report has been added to ResearchAndMarkets.com's offering.
The global Human Immunodeficiency Virus (HIV) diagnosis & treatment market is expected to grow at a CAGR of 7.6% during 2017-2022.
According to world health organization (WHO), it is a main global public health issue. In 2015, 1.2 million people died with HIV related infections across the globe and approximately 36.8 million people are currently suffering from HIV. As a result, the global HIV diagnosis and treatment market is rapidly growing, and continuously working on trials for the proper diagnosis followed by treatment.
The market for HIV diagnosis and treatment market is growing at the pace, and also the increasing occurrence of HIV/AIDS infection globally boosting is the market, also government taking initiatives diagnosis and treatment and increasing in blood donations and blood transfusions and increasing awareness about HIV/AIDS.
One of the major reason for the increase in the number of HIV infection across the globe, includes, changing lifestyle, injection drug usage, and lack of awareness and unprotected sex in some region. A prime factor driving the market for HIV diagnosis and treatment market is government and Non-governmental organizations (NGOs) efforts to initiate against HIV/AIDS.
Key Topics Covered
1. Report Summary
2. Market Overview and Insights
3. Market Determinant
4. Market Segmentation
5. Competitive Landscape
6. Regional Analysis
7. Company Profiles
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Inc.
- F. Hoffmann-La Roche Ltd
- Gilead
- Glaxosmithkline Plc.
- Hologic Inc.
- VIIV Healthcare Group of Companies
- Janssen Diagnostics
- Johnson & Johnson Services
- Merck & Co. Inc.
- Mylan Inc.
- Partec
- Pointcare Technologies Inc.
- Qiagen
- Roche Diagnostics
- Siemens Healthcare
- Sysmex Corporation
- Zyomyx Inc.
For more information about this report visit https://www.researchandmarkets.com/research/cn7rz6/global_hiv?w=4
